Search

Your search keyword '"Giglio, Pierre"' showing total 45 results

Search Constraints

Start Over You searched for: Author "Giglio, Pierre" Remove constraint Author: "Giglio, Pierre" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
45 results on '"Giglio, Pierre"'

Search Results

1. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

3. Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma

6. Dose-escalated accelerated hypofractionation for elderly or frail patients with a newly diagnosed glioblastoma

7. A Randomized, Double-blind, Phase 3 Study of Vorasidenib Versus Placebo in Patients with Mutant IDH1/2 Diffuse Glioma (INDIGO): Analysis of Health-related Quality of Life, Neurocognition and Seizures (PL5.003)

9. Final report of the phase II NEXT/CNS-GCT-4 trial: GemPOx followed by marrow-ablative chemotherapy for recurrent intracranial germ cell tumors.

10. Unsupervised machine learning models reveal predictive clinical markers of glioblastoma patient survival using white blood cell counts prior to initiating chemoradiation

11. CTNI-53. ESTABLISHING A PHASE I AND RANDOMIZED PHASE II TRIAL OF SELINEXOR AND TEMOZOLOMIDE IN GLIOBLASTOMA

12. QOL-26. A RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY OF VORASIDENIB VS PLACEBO IN PATIENTS WITH MUTANT IDH1/2DIFFUSE GLIOMA (INDIGO): ANALYSIS OF HEALTH-RELATED QUALITY OF LIFE, NEUROCOGNITION AND SEIZURES

13. CTNI-51. A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF VORASIDENIB VS PLACEBO IN PATIENTS WITH MUTANT IDH1/2 DIFFUSE GLIOMA (INDIGO): EXPLORATORY ANALYSIS OF VARIANT ALLELE FREQUENCY AND PROGRESSION-FREE SURVIVAL

14. Final Report of the Phase II NEXT/CNS-GCT-4 Trial: GemPOx followed by Marrow-ablative Chemotherapy for Recurrent Intracranial Germ Cell Tumors

17. Unsupervised machine learning models reveal predictive markers of glioblastoma patient survival using white blood cell counts prior to initiating chemoradiation

18. Supplementary Data from Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma

19. Data from Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma

20. Supplementary Table 1 from Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma

21. Supplementary Figure from Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study

22. Supplementary Table from Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study

23. Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.

24. Correspondence comprehensive characterization of a brainstem aggregoma (light and heavy chain deposition disease).

25. Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma

27. EXTH-91. GALECTIN-3 INHIBITOR PAIRED WITH FOCAL LOW-INTENSITY NONINVASIVE TDCS CAN ACHIEVE MAXIMAL THERAPEUTIC BENEFIT IN CLINICALLY RELEVANT MENINGIOMA MOUSE MODELS

28. CTIM-27. AUTOLOGOUS TUMOR LYSATE-LOADED DENDRITIC CELL VACCINATION IMPROVES SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA: SURVIVAL RESULTS FROM A PHASE 3 TRIAL

29. NIMG-78. DEVELOPMENT OF A PRECLINICAL GLIOBLASTOMA MURINE MODEL FOR THE ASSESSMENT OF RADIATION NECROSIS USING DIFFUSION KURTOSIS IMAGING

30. CTNI-50. A RANDOMIZED PHASE 2 TRIAL OF CEDIRANIB/OLAPARIB VERSUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: UPDATED RESULTS

31. QLTI-02. AUTOMATED INTRAOPERATIVE RESECTION TECHNOLOGY GENERATES INCREASED TISSUE YIELD AND IMPROVED BIOLOGICAL PRESERVATION OF BRAIN TUMOR SPECIMENS FOR NEURO-ONCOLOGY RESEARCH

33. Small Molecules and Immunotherapy Agents for Enhancing Radiotherapy in Glioblastoma

34. Multicenter phase 2 trial of the PARP inhibitor (PARPi) olaparib in recurrent IDH1 and IDH2-mutant contrast-enhancing glioma.

35. Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study

36. Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study

37. Phase I study of trametinib in combination with whole brain radiation therapy for brain metastases

39. Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study

40. Abstract P044: A phase 1 dose escalation study of protein arginine methyltransferase 5 (PRMT5) brain penetrant inhibitor PRT811 in patients with advanced solid tumors, including recurrent high-grade gliomas

41. Contributors

42. Contributors

43. INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation

45. Unsupervised machine learning models reveal predictive markers of glioblastoma patient survival using white blood cell counts prior to initiating chemoradiation.

Catalog

Books, media, physical & digital resources